Michael Glickman
banner
michaelglickman.bsky.social
Michael Glickman
@michaelglickman.bsky.social
Physician Scientist interested in all things mycobacterial: pathogen, model system, and cancer therapy. Immunology program/ID MSK. Opinions are mine and do not represent those of my employer, MSK.

https://scholar.google.com/citations?hl=en&user=xriihOcAA
We show that these iPSC derived alveolar macrophages, which we call AM-L (like), resemble bonafide AMs at baseline and with Mtb infection, leveraging the insights of our collaborators in the Hawn lab published here:
journals.aai.org/jimmunol/art...
July 28, 2025 at 9:43 PM
To faciliate human AM studies, we derived macrophage subtypes from iPSCs under distinct cytokines, including GM-CSF, which is required for development of AMs.
July 28, 2025 at 9:43 PM
And also show that placing the ALFA tag at different places in a multidomain protein (Pks13) allows for domain specific interactomes:
March 25, 2025 at 2:54 PM
And can be used for proximity proteomics by fusing NBALFA to TurboID. We present a full workflow for proximity proteomics in M. smegmatis and M. tuberculosis. Here shown for the mycolic acid biosynthetic protein Pks13:
March 25, 2025 at 2:54 PM
Allison reasoned that placing the ALFA tag on the target protein and expressing the high affinity anti-ALFA nanobody fused to various functional domains in live mycobacteria would be a versatile system. We show that such an approach enables faitful localization of proteins, here shown for MmpL3...
March 25, 2025 at 2:54 PM
Agree, very fun. I set the word frequency to 3. 🦠 #microsky
February 6, 2024 at 12:52 PM
Important point, the name is misleading, as most names are. Here is the cdc map from 2019 for spotted fever group rickettsiosis.
December 9, 2023 at 5:22 PM